Ocular Therapeutix shares surge 11.64% intraday as Q4 loss beats estimates and Phase 3 SOL-1 data to be unveiled at Macula Society meeting.

Ocular Therapeutix surged 11.64% intraday, driven by better-than-expected fourth-quarter results (a $0.29 loss per share, narrower than the $0.32 forecast), plans to present Phase 3 SOL-1 trial data at the 2026 Macula Society meeting, and a $737.1 million cash balance as of December 31, 2025, which the company said will fund operations through 2028. The firm also announced plans to submit a new drug application for AXPAXLI for wet age-related macular degeneration.